EPS for AVEO Pharmaceuticals, Inc. (AVEO) Expected At $-0.06; Brown Forman Has 1.11 Sentiment

April 20, 2018 - By Ellis Scott

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Logo

Brown Forman Corp (BFB) investors sentiment decreased to 1.11 in 2017 Q4. It’s down -0.02, from 1.13 in 2017Q3. The ratio fall, as 178 funds opened new or increased equity positions, while 160 sold and reduced their positions in Brown Forman Corp. The funds in our database now have: 93.87 million shares, up from 92.60 million shares in 2017Q3. Also, the number of funds holding Brown Forman Corp in top ten equity positions increased from 6 to 11 for an increase of 5. Sold All: 26 Reduced: 134 Increased: 119 New Position: 59.

Analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $-0.06 EPS on May, 3.They anticipate $0.06 EPS change or 50.00% from last quarter’s $-0.12 EPS. After having $-0.08 EPS previously, AVEO Pharmaceuticals, Inc.’s analysts see -25.00% EPS growth. The stock decreased 2.45% or $0.0649 during the last trading session, reaching $2.5851. About 147,997 shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has risen 351.31% since April 20, 2017 and is uptrending. It has outperformed by 339.76% the S&P500.

The stock decreased 1.08% or $0.6 during the last trading session, reaching $54.86. About 106,730 shares traded or Infinity% up from the average. Brown-Forman Corporation (BFB) has 0.00% since April 20, 2017 and is . It has underperformed by 11.55% the S&P500.

Ratings analysis reveals 33% of Brown-Forman’s analysts are positive. Out of 6 Wall Street analysts rating Brown-Forman, 2 give it “Buy”, 1 “Sell” rating, while 3 recommend “Hold”. The lowest target is $42.0 while the high is $110.0. The stock’s average target of $75.50 is 37.62% above today’s ($54.86) share price. BFB was included in 7 notes of analysts from July 21, 2015. The company was initiated on Tuesday, July 21 by Sterne Agee CRT. On Monday, September 28 the stock rating was downgraded by Morgan Stanley to “Underweight”. The company was downgraded on Thursday, December 22 by SunTrust. Stifel Nicolaus maintained Brown-Forman Corporation (NYSE:BFB) on Thursday, December 8 with “Hold” rating. RBC Capital Markets downgraded Brown-Forman Corporation (NYSE:BFB) rating on Monday, January 4. RBC Capital Markets has “Sector Perform” rating and $109.0 target. Credit Suisse initiated Brown-Forman Corporation (NYSE:BFB) on Friday, September 16 with “Outperform” rating. Stifel Nicolaus maintained Brown-Forman Corporation (NYSE:BFB) rating on Thursday, August 27. Stifel Nicolaus has “Buy” rating and $110.0 target.

Since January 1, 0001, it had 0 insider purchases, and 7 sales for $4.33 million activity.

Atlas Browninc. holds 11.13% of its portfolio in Brown-Forman Corporation for 905,660 shares. Underhill Investment Management Llc owns 218,470 shares or 7.15% of their US portfolio. Moreover, Pitcairn Co has 5.08% invested in the company for 741,537 shares. The New York-based Tirschwell & Loewy Inc has invested 3.72% in the stock. Rbo & Co Llc, a California-based fund reported 153,087 shares.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $398.50 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals had 15 analyst reports since March 30, 2016 according to SRatingsIntel. FBR Capital maintained it with “Buy” rating and $5.0 target in Thursday, March 22 report. As per Wednesday, August 9, the company rating was maintained by Piper Jaffray. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Overweight” rating by Piper Jaffray on Thursday, May 19. The firm earned “Buy” rating on Tuesday, March 13 by FBR Capital. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has “Buy” rating given on Thursday, March 29 by Piper Jaffray. Piper Jaffray upgraded the stock to “Buy” rating in Monday, August 28 report. The firm has “Outperform” rating given on Wednesday, March 30 by FBR Capital. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has “Buy” rating given on Thursday, October 5 by Piper Jaffray. The rating was maintained by FBR Capital on Tuesday, January 16 with “Buy”. The rating was maintained by FBR Capital on Monday, February 12 with “Buy”.

Since April 6, 2018, it had 10 insider purchases, and 0 insider sales for $21.15 million activity. 920,976 shares valued at $2.12M were bought by Florence Anthony A. Jr. on Friday, April 6. MAKOWER JOSHUA bought $2.12 million worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Friday, April 6. $2.12M worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares were bought by BASKETT FOREST. Sakoda Jon also bought $2.12 million worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Friday, April 6. $2.12M worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by Growth Equity Opportunities IV – LLC on Friday, April 6. MOTT DAVID M also bought $2.12M worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares. SANDELL SCOTT D had bought 920,976 shares worth $2.12M on Friday, April 6.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>